1. Home
  2. VIGL vs SKYE Comparison

VIGL vs SKYE Comparison

Compare VIGL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • SKYE
  • Stock Information
  • Founded
  • VIGL 2020
  • SKYE 2012
  • Country
  • VIGL United States
  • SKYE United States
  • Employees
  • VIGL N/A
  • SKYE N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • VIGL Health Care
  • SKYE Health Care
  • Exchange
  • VIGL Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • VIGL 89.3M
  • SKYE 80.7M
  • IPO Year
  • VIGL 2022
  • SKYE N/A
  • Fundamental
  • Price
  • VIGL $2.66
  • SKYE $3.41
  • Analyst Decision
  • VIGL Strong Buy
  • SKYE Buy
  • Analyst Count
  • VIGL 5
  • SKYE 6
  • Target Price
  • VIGL $21.00
  • SKYE $18.67
  • AVG Volume (30 Days)
  • VIGL 2.6M
  • SKYE 178.5K
  • Earning Date
  • VIGL 03-25-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • VIGL N/A
  • SKYE N/A
  • EPS Growth
  • VIGL N/A
  • SKYE N/A
  • EPS
  • VIGL N/A
  • SKYE N/A
  • Revenue
  • VIGL N/A
  • SKYE N/A
  • Revenue This Year
  • VIGL N/A
  • SKYE N/A
  • Revenue Next Year
  • VIGL N/A
  • SKYE N/A
  • P/E Ratio
  • VIGL N/A
  • SKYE N/A
  • Revenue Growth
  • VIGL N/A
  • SKYE N/A
  • 52 Week Low
  • VIGL $1.49
  • SKYE $2.31
  • 52 Week High
  • VIGL $6.06
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 66.89
  • SKYE 52.82
  • Support Level
  • VIGL $2.53
  • SKYE $2.70
  • Resistance Level
  • VIGL $2.88
  • SKYE $3.29
  • Average True Range (ATR)
  • VIGL 0.30
  • SKYE 0.45
  • MACD
  • VIGL 0.06
  • SKYE 0.05
  • Stochastic Oscillator
  • VIGL 70.98
  • SKYE 41.27

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: